According to a Michigan medical study, most patients with mild COVID-19 infections produce antibodies that last up to 6 months and protect against reinfection.
The researchers analyzed about 130 subjects with the COVID-19 disease confirmed by PCR between the first infection and 3 to 6 months. Three patients were hospitalized and the rest were treated as outpatients and experienced mild infections with symptoms such as headache, chills, and loss of taste and smell.
Result is, Microbiology spectrum, Approximately 90% of participants showed spike and nucleocapsid antibody responses, revealing that all but one showed sustained antibody levels at follow-up.
“Previously, there were many concerns that only people with severe COVID-19 would have a strong antibody response to infection,” said the lead author of the treatise, Allergy and Immunology in Michigan Medicine. Dr. Charles Schuler, a clinical assistant professor, said. “People with mild seizures of COVID-19 have shown that they really worked well after infection, made antibodies and maintained them.”
Participants in the prospective study were either health care workers in Michigan medicine or patients at high risk of exposure to COVID-19. Most subjects participated in a previous study by the same research team and found that COVID antibody testing was effective in predicting previous infections.
During the observation period, none of the antibody-producing subjects were re-infected compared to 15 antibody-negative patients. Schuler’s team also found that the ability of antibodies to neutralize COVID-19 was not significantly different from the first visit that occurred 3 months after infection to the second visit at 6 months. bottom.
“Several studies suggest that antibodies to COVID-19 decline over time, but these findings provide strong positive evidence of long-term immunity to those who produce an immune response to mild infections. “Masu,” said Mary H. Weiser, Founding Director of the Food Allergy Center in Paper and Michigan Medicine. “As far as we know, this is the first prospective study demonstrating such a risk reduction of clinical reinfection in this particular type of population.”
Impact on COVID vaccination
The research team is currently analyzing a sample of this group of subjects taken up to one year after infection to further evaluate the antibody response. Meanwhile, they concluded that patients with COVID-19 could delay vaccination for 90 days after the end of infection. The Center for Disease Control and Prevention recommends that those treated with monoclonal antibodies or convalescent plasma wait 90 days after receiving treatment before vaccination, while others recover from COVID-19 and ” You must wait until you meet the criteria for stopping quarantine.
According to a study conducted in Kentucky, unvaccinated people who are already infected with COVID-19 are 2.34 times more likely to be infected than those who are fully vaccinated. It provides additional protection against. “
In addition, the study was conducted between March 2020 and February 2021 months before the highly infectious delta mutant became the predominant strain of COVID in the United States.
As the number of cases and hospitalizations increases, leaving unvaccinated is associated with “high” immunity, Schuler said.
“These results are encouraging for those who are already running gauntlets with COVID-19 infection,” he said. “But it is not advisable to cite this study as a reason not to be vaccinated for people who have never been infected. Vaccination is infectious, hospitalized, without actual infection. Reduces risk and death from COVID-19. Achieves spontaneous immunity by postponing vaccination. Supporting infection is worth experiencing discomfort, risk to oneself, risk to others there is not.”